Dreesen E - Search Results

1

Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.

Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D. Murias S, et al. Among authors: dreesen e. Ther Drug Monit. 2017 Aug;39(4):370-378. doi: 10.1097/FTD.0000000000000423. Ther Drug Monit. 2017. PMID: 28703718 Review.

2

Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole.

Jansen AME, Snijdelaar K, Keizer RJ, Spriet I, Dreesen E, Brüggemann RJM, Ter Heine R. Jansen AME, et al. Among authors: dreesen e. Clin Pharmacokinet. 2024 May;63(5):645-656. doi: 10.1007/s40262-024-01361-8. Epub 2024 Mar 26. Clin Pharmacokinet. 2024. PMID: 38532053 Free PMC article.

3

Do we perceive sensations inside and outside of our body differently? Perceptual, emotional, and behavioral differences between visceral and somatic sensation, discomfort, and pain.

Guadagnoli L, Hoffert Y, Den Hond S, Dreesen E, van Ryckeghem D, Van Damme S, Zaman J, Van Oudenhove L. Guadagnoli L, et al. Among authors: dreesen e. Neurogastroenterol Motil. 2024 Mar 24:e14787. doi: 10.1111/nmo.14787. Online ahead of print. Neurogastroenterol Motil. 2024. PMID: 38523349

4

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.

Dreesen E, Gils A, Vermeire S. Dreesen E, et al. Curr Drug Targets. 2018;19(7):757-776. doi: 10.2174/1389450117666160307144329. Curr Drug Targets. 2018. PMID: 26953243 Review.

5

Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.

Passot C, Pouw MF, Mulleman D, Bejan-Angoulvant T, Paintaud G, Dreesen E, Ternant D. Passot C, et al. Among authors: dreesen e. Ther Drug Monit. 2017 Aug;39(4):322-326. doi: 10.1097/FTD.0000000000000389. Ther Drug Monit. 2017. PMID: 28703717 Review.

6

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Dreesen E, et al. Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. Clin Pharmacol. 2017. PMID: 29042821 Free PMC article. Review.

7

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time.

Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A. Bian S, et al. Among authors: dreesen e. Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208. doi: 10.1097/MIB.0000000000001255. Inflamm Bowel Dis. 2017. PMID: 29140943

8

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S. van Hoeve K, et al. Among authors: dreesen e. Ther Drug Monit. 2019 Jun;41(3):317-324. doi: 10.1097/FTD.0000000000000601. Ther Drug Monit. 2019. PMID: 30633088

9

Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases.

Dreesen E, Gils A. Dreesen E, et al. Ther Drug Monit. 2019 Apr;41(2):131-141. doi: 10.1097/FTD.0000000000000571. Ther Drug Monit. 2019. PMID: 30883507 Review.

10

How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?

Vermeire S, Dreesen E, Papamichael K, Dubinsky MC. Vermeire S, et al. Among authors: dreesen e. Clin Gastroenterol Hepatol. 2020 May;18(6):1291-1299. doi: 10.1016/j.cgh.2019.09.041. Epub 2019 Oct 4. Clin Gastroenterol Hepatol. 2020. PMID: 31589978 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page